Characteristics of 21 published prospective studies of t-PA antigen, D-dimer and VWF.

Abbreviations:AmB, American Bioproducts; AmD, American Diagnostica; AP, angina pectoris; ARIC, Atherosclerosis Risk in Communities Study; BRHS, British Regional Heart Study; BWHHS, British Women’s Heart and Health Study; Caerphilly, Caerphilly Prospective Study; CHD, coronary heart disease endpoint (composed of nonfatal myocardial infarction and coronary death); CHS, Cardiovascular Health Study; CS, coronary surgery; DStago, Diagnostica Stago; EAS, Edinburgh Artery Study; ELISA, enzyme-linked immunosorbent assay; FHS, Framingham Heart Study; Fletcher, Fletcher Challenge Study; Glostrup, Glostrup population studies; IRE, Ireland; IT, immunoturbidometry; MESA, Multi-Ethnic Study of Atherosclerosis; MI, myocardial infarction; NPHS-I, Northwick Park Heart Study I; NSHDS, Northern Sweden Health and Diseases Study cohort; PHS, Physicians’ Health Study; PRIME, Prospective Epidemiological Study of Myocardial Infarction; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; NI, Northern Ireland; NL, Netherlands; NR, not reported; NZ, New Zealand; R&D Sys, R&S Systems; RE, rocket electrophoresis; Rotterdam, Rotterdam Study; SCO, Scotland; Speedwell, Speedwell Study; Three-City, Three-City cohort study; WHI, Women’s Health Initiative; WOSCOPS, The West of Scotland Coronary Prevention Study.*Reports with two different study baselines and non-overlapping follow-up periods are available.†Median.‡Maximum.§Range.||Geometric mean.